Ultralife Corporation, together with its subsidiaries, designs, manufactures, installs, and maintains power, and communication and electronics systems worldwide. The company serves government, defense, and commercial sectors. The company operates in two segments, Battery & Energy Products and Communications Systems. The Battery & Energy Products segment offers lithium 9-volt, cylindrical, thin lithium manganese dioxide, rechargeable, and other non-rechargeable batteries; lithium-ion cells, multi-kilowatt module lithium ion battery systems, and uninterruptable power supplies; and rugged military and commercial battery charging systems and accessories, including smart chargers, multi-bay charging systems, and various cables. The Communications Systems segment provides communications systems and accessories to support military communications systems, such as radio frequency amplifiers, power supplies and cables, connector assemblies, amplified speakers, equipment mounts, case equipment, man-portable systems, and integrated communication systems for fixed or vehicle applications comprising vehicle adapters, vehicle installed power enhanced rifleman appliqué systems, and SATCOM systems. This segment's military communications systems and accessories are designed to enhance and extend the operation of communications equipment, such as vehicle-mounted, manpack, and handheld transceivers. It sells its products under the Ultralife, Lithium Power, McDowell Research, AMTI, ABLE, ACCUTRONICS, ACCUPRO, ENTELLION, SWE Southwest Electronic Energy Group, SWE DRILL-DATA, and SWE SEASAFE brands through original equipment manufacturers, and industrial and defense supply distributors, as well as directly to the United States and international defense departments. In addition, the company sells its 9-volt battery to the broader consumer market through national and regional retail chains and online retailers. The company was founded in 1990 and is headquartered in Newark, New York.
IPO Year: 1992
Exchange: NASDAQ
Website: ultralifecorporation.com
8-K - ULTRALIFE CORP (0000875657) (Filer)
10-Q - ULTRALIFE CORP (0000875657) (Filer)
8-K - ULTRALIFE CORP (0000875657) (Filer)
8-K - ULTRALIFE CORP (0000875657) (Filer)
SD - ULTRALIFE CORP (0000875657) (Filer)
DEF 14A - ULTRALIFE CORP (0000875657) (Filer)
DEFA14A - ULTRALIFE CORP (0000875657) (Filer)
EFFECT - ULTRALIFE CORP (0000875657) (Filer)
S-3/A - ULTRALIFE CORP (0000875657) (Filer)
10-K/A - ULTRALIFE CORP (0000875657) (Filer)
NEWARK, N.Y., Nov. 22, 2022 (GLOBE NEWSWIRE) -- The Board of Directors of Ultralife Corporation ("Ultralife" or the "Company") (NASDAQ:ULBI) has appointed Michael E. Manna as the Company's President & CEO and as a member of the Board of Directors effective immediately to replace Michael D. Popielec who is leaving the Company. Mr. Popielec will remain with Ultralife as an employee for a sixty-day period ending January 20, 2023 in an advisory role to ensure a smooth leadership transition. In addition to his new role, Mike Manna will retain his leadership position for the Company's Battery & Energy Products segment which he held prior to his appointment as President & CEO. "Over the past twe
Benchmark initiated coverage of Ultralife with a rating of Buy and set a new price target of $12.00
The Benchmark Company initiated coverage of Ultralife with a rating of Buy and set a new price target of $12.00
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
SC 13D/A - ULTRALIFE CORP (0000875657) (Subject)
SC 13G - ULTRALIFE CORP (0000875657) (Subject)
SC 13G/A - ULTRALIFE CORP (0000875657) (Subject)
SC 13G - ULTRALIFE CORP (0000875657) (Subject)
SC 13G/A - ULTRALIFE CORP (0000875657) (Subject)
SC 13G - ULTRALIFE CORP (0000875657) (Subject)
SC 13G/A - ULTRALIFE CORP (0000875657) (Subject)
SC 13G - ULTRALIFE CORP (0000875657) (Subject)
NEWARK, N.Y., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) completed its acquisition of all outstanding shares of Electrochem Solutions, Inc. ("Electrochem") for $50.0 million in cash from Integer Holdings Corporation (NYSE:ITGR) on October 31, 2024. "I am thrilled to welcome Electrochem to the growing Ultralife Team as another valued member that shares our core values, operating philosophy and strong commitment to both our associates and our long-standing customers. Having achieved our target of closing the acquisition of Electrochem by the end of October, we now look forward to working closely with Khristine Carroll, President – Electrochem, and her experienced
NEWARK, N.Y., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its third quarter results for the period ended September 30, 2024 before the market opens on Friday, November 8, 2024. The Company is reporting third quarter results later than its customary date after its quarter end in order to accommodate the expected closing of its acquisition of Electrochem Solutions, Inc. by the end of October. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on November 8, 2024. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable
NEWARK, N.Y., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) has signed a stock purchase agreement to acquire all outstanding shares of Electrochem Solutions, Inc. ("Electrochem") to include its state-of-the-art ISO certified technology and manufacturing facility for $50.0 million in cash from Integer Holdings Corporation (NYSE:ITGR), subject to customary working capital adjustments. The transaction is expected to close by the end of October. Ultralife expects to finance the transaction through its primary lender. Based in Raynham, MA and with over forty years of battery technology experience in critical applications, Electrochem designs and manufactures primary li
PLANO, Texas, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device contract development and manufacturing organization (CDMO), today announced it has entered into an agreement to divest its Electrochem business, which focuses on non-medical applications for the energy, military and environmental sectors, to Ultralife Corporation (NASDAQ:ULBI). Ultralife is acquiring Electrochem for $50 million in cash, subject to customary working capital adjustments, and the transaction is expected to close by the end of October. "The divestiture of our non-medical business is another example of Integer managing our portfolio to accomplish our strategic fi
NEWARK, N.Y., July 25, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the second quarter ended June 30, 2024 with the following highlights: Sales of $43.0 million compared to $42.7 million for the 2023 second quarter, including 8.3% growth in Battery & Energy Products sales to its highest level in the Company's history for this segmentGross profit of $11.6 million, or 26.9% of revenue, compared to $10.6 million, or 24.8% of revenue, for the 2023 second quarterOperating income of $3.9 million, a 6.9% increase over the 2023 second quarterGAAP EPS of $0.18 compared to $0.21 which included recognition of our Employee Retention Credit equivalent to
NEWARK, N.Y., July 11, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its second quarter results for the period ended June 30, 2024 before the market opens on Thursday, July 25, 2024. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on July 25, 2024. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register.vevent.com/register/BI3ab77e4ff3d049f3b130d6d227043bba. This will elimin
NEWARK, N.Y., July 01, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) has been added to the Russell 2000® Index and the broad market Russell 3000® Index as part of the 2024 annual reconstitution of the index, effective at the open of the U.S. equity market today, July 1, 2024. "The inclusion of Ultralife in the Russell 2000® Index, one of the most widely used performance benchmarks for small-cap companies, testifies to the substantial improvement in the Company's financial profile and earnings power as we began to realize returns on our customer-driven new product investments and to recapture margins while continuing to advance our transformational projects for our commercia
NEWARK, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the first quarter ended March 31, 2024 with the following highlights: Sales of $41.9 million representing a 31.4% year-over-year increase, including 54.7% growth in medical market salesGross profit of $11.5 million, or 27.4% of revenue, compared to $7.4 million, or 23.3% of revenue for the 2023 first quarterOperating income of $4.1 million versus breakeven for the 2023 first quarterGAAP EPS of $0.18 compared to a loss of $0.02 for the 2023 first quarterAdjusted EBITDA of $5.2 million, a four-fold gain compared to $1.2 million last yearBacklog of $97.4 million exiting the 202
NEWARK, N.Y., April 11, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its first quarter results for the period ended March 31, 2024 before the market opens on Thursday, April 25, 2024. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on April 25, 2024. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register.vevent.com/register/BI5d712724df6d4c65bb6496c4ce2d606f. This will elimi
NEWARK, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter Highlights: Sales of $44.5 million representing a 23.4% year-over-year increaseHighest medical sales quarter in Company's historyOperating income of $3.6 million versus $0.2 million for the 2022 fourth quarterAdjusted EPS of $0.18 compared to a loss of $0.03 for the 2022 fourth quarterAdjusted EBITDA of $4.8 million representing a 134.8% year-over-year increaseBacklog of $103.5 million exiting 2023, a 2.4% sequential increase over third quarter Fiscal Year 2023 Highlights: Sales of $158.6 million
NEWARK, N.Y., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its third quarter results for the period ended September 30, 2024 before the market opens on Friday, November 8, 2024. The Company is reporting third quarter results later than its customary date after its quarter end in order to accommodate the expected closing of its acquisition of Electrochem Solutions, Inc. by the end of October. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on November 8, 2024. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable
NEWARK, N.Y., July 25, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the second quarter ended June 30, 2024 with the following highlights: Sales of $43.0 million compared to $42.7 million for the 2023 second quarter, including 8.3% growth in Battery & Energy Products sales to its highest level in the Company's history for this segmentGross profit of $11.6 million, or 26.9% of revenue, compared to $10.6 million, or 24.8% of revenue, for the 2023 second quarterOperating income of $3.9 million, a 6.9% increase over the 2023 second quarterGAAP EPS of $0.18 compared to $0.21 which included recognition of our Employee Retention Credit equivalent to
NEWARK, N.Y., July 11, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its second quarter results for the period ended June 30, 2024 before the market opens on Thursday, July 25, 2024. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on July 25, 2024. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register.vevent.com/register/BI3ab77e4ff3d049f3b130d6d227043bba. This will elimin
NEWARK, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the first quarter ended March 31, 2024 with the following highlights: Sales of $41.9 million representing a 31.4% year-over-year increase, including 54.7% growth in medical market salesGross profit of $11.5 million, or 27.4% of revenue, compared to $7.4 million, or 23.3% of revenue for the 2023 first quarterOperating income of $4.1 million versus breakeven for the 2023 first quarterGAAP EPS of $0.18 compared to a loss of $0.02 for the 2023 first quarterAdjusted EBITDA of $5.2 million, a four-fold gain compared to $1.2 million last yearBacklog of $97.4 million exiting the 202
NEWARK, N.Y., April 11, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its first quarter results for the period ended March 31, 2024 before the market opens on Thursday, April 25, 2024. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on April 25, 2024. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register.vevent.com/register/BI5d712724df6d4c65bb6496c4ce2d606f. This will elimi
NEWARK, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter Highlights: Sales of $44.5 million representing a 23.4% year-over-year increaseHighest medical sales quarter in Company's historyOperating income of $3.6 million versus $0.2 million for the 2022 fourth quarterAdjusted EPS of $0.18 compared to a loss of $0.03 for the 2022 fourth quarterAdjusted EBITDA of $4.8 million representing a 134.8% year-over-year increaseBacklog of $103.5 million exiting 2023, a 2.4% sequential increase over third quarter Fiscal Year 2023 Highlights: Sales of $158.6 million
NEWARK, N.Y., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its fourth quarter results for the period ended December 31, 2023 before the market opens on Thursday, February 15, 2024. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on February 15, 2024. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register.vevent.com/register/BI9f2b6fae66954f53b4517cbe89148738. This
NEWARK, N.Y., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the third quarter ended September 30, 2023 with the following highlights: Sales of $39.5 million representing an 18.8% year-over-year increaseOperating income of $2.1 million versus a loss of $0.6 million for the 2022 third quarterAdjusted EPS of $0.10 compared to a loss of $0.03 for the 2022 third quarterAdjusted EBITDA of $3.5 million representing a 177.3% year-over-year increaseBacklog of $101.1 million exiting the 2023 third quarter "Driven by continuing strong demand from our government/defense and medical customers, sales grew 19% for both the 2023 third quarter and th
NEWARK, N.Y., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its third quarter results for the period ended September 30, 2023 before the market opens on Thursday, October 26, 2023. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET on October 26, 2023. Please see the call-in procedures which follow below. NOTE TO THOSE PLANNING TO PARTICIPATE BY PHONE: To ensure a fast and reliable connection to our investor conference call, we require participants dialing in by phone to pre-register using this link prior to the call: https://register.vevent.com/register/BI7f14d2264d2242c1adb217d21d75ab21. This wil
NEWARK, N.Y., July 27, 2023 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) reported operating results for the second quarter ended June 30, 2023 with the following highlights: Sales of $42.7 million representing a 32.9% year-over-year increaseOperating income of $3.7 million compared to $0.8 million for the 2022 second quarterAdjusted EPS of $0.29 compared to $0.03 for the 2022 second quarterAdjusted EBITDA of $6.3 million or 14.7% of sales versus $2.2 million or 6.8% last yearBacklog increase to $110.9 million, the highest level in the Company's history "Driven by surging demand from our government/defense and medical customers, we delivered a 33% year-over-year sal
Ultralife (NASDAQ:ULBI) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.14 by 57.14 percent. This is a 1200 percent increase over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $42.98 million which beat the analyst consensus estimate of $42.00 million by 2.34 percent. This is a 34.68 percent increase over sales of $31.92 million the same period last year.
Ultralife Corporation (NASDAQ:ULBI) has been added to the Russell 2000® Index and the broad market Russell 3000® Index as part of the 2024 annual reconstitution of the index, effective at the open of the U.S. equity market today, July 1, 2024.
Benchmark analyst Josh Sullivan maintains Ultralife (NASDAQ:ULBI) with a Buy and raises the price target from $13 to $14.
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling by around 100 points on Thursday. The Dow traded down 1.20% to 37,998.27 while the NASDAQ fell 0.85% to 15,578.58. The S&P 500 also fell, dropping, 0.70% to 5,035.88. Check This Out: How To Earn $500 A Month From T-Mobile US Stock Ahead Of Q1 Earnings Report Leading and Lagging SectorsMaterials shares rose by 0.7% on Thursday. In trading on Thursday, communication services shares dipped by 4%. Top Headline Shares of Bristol Myers Squibb & Co (NYSE:BMY) fell more than 8% during Thursday's session after the company swung to a loss in the first quarter. The company posted first-quarter re
Shares of Caterpillar Inc. (NYSE:CAT) fell sharply during Thursday's session after the company reported better-than-expected first-quarter EPS but missed revenue estimates. Caterpillar reported a first-quarter fiscal 2024 revenue of $15.8 billion, a slight decrease of 0.4% year-over-year, missing the consensus of $16.216 billion. CAT's adjusted earnings of $5.60 per share, compared to $4.91 a year ago, topped the consensus of $5.14, according to data from Benzinga Pro. Caterpillar shares dipped 6.6% to $339.37 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Barfresh Food Group, Inc. (NASDAQ:BRFH) surged 87.2% to $2.05. Safe & Green Holdin
Gainers Safe & Green Holdings (NASDAQ:SGBX) shares moved upwards by 61.5% to $0.23 during Thursday's regular session. The market value of their outstanding shares is at $4.2 million. P.A.M. Transportation (NASDAQ:PTSI) shares moved upwards by 20.56% to $17.53. The company's market cap stands at $386.2 million. Ultralife (NASDAQ:ULBI) stock rose 19.53% to $10.44. The company's market cap stands at $171.6 million. As per the press release, Q1 earnings came out today. Freight Technologies (NASDAQ:FRGT) stock rose 18.39% to $1.03. The company's market cap stands at $2.5 million. Montana Technologies (NASDAQ:AIRJ) shares moved upwards by 14.12% to $12.04. The company's market cap stands at $
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling by around 250 points on Thursday. The Dow traded down 1.55% to 37,864.79 while the NASDAQ fell 1.60% to 15,460.95. The S&P 500 also fell, dropping, 1.16% to 5,012.94. Check This Out: How To Earn $500 A Month From T-Mobile US Stock Ahead Of Q1 Earnings Report Leading and Lagging SectorsEnergy shares fell by just 0.2% on Thursday. In trading on Thursday, communication services shares dipped by 5.3%. Top Headline Merck & Co., Inc. (NYSE:MRK) reported better-than-expected first-quarter financial results and raised its 2024 guidance. Merck posted adjusted earnings of $2.07 per share, beating m
U.S. stocks were lower, with the Dow Jones falling over 600 points on Thursday. Shares of Sanofi SA (NASDAQ:SNY) rose sharply during Thursday's session following better-than-expected first-quarter earnings. Sanofi reported first-quarter operating income of 2.8 billion euros, down 14.7% Y/Y and 4.2% on constant currency. The French drugmaker reported adjusted EPS of 97 cents (1.78 euros), beating the consensus estimate of 94 cents, according to data from Benzinga Pro. Sanofi shares climbed 5.5% to $49.15 on Thursday. Here are some other big stocks recording gains in today's session. P.A.M. Transportation Services, Inc. (NASDAQ:PTSI) jumped 19.8% to $17.42 after the company ann
ULBI: 26% | Ultralife shares are trading higher after the company reported better-than-expected Q1 financial results.CDTX: 41% | Cidara Therapeutics shares are trading higher after the company announced the divestiture of rezafungin to Mundipharma, reacquired global development and commercial rights to CD388 and announced $240 million in private placement financing. OPTN: 36% | Optinose Provides Corporate Updates; Expects To Produce Positive Income From Operations For Full Year 2025
Gainers Intelligent Living (NASDAQ:ILAG) shares rose 56.6% to $0.85 during Thursday's pre-market session. The market value of their outstanding shares is at $15.2 million. Ultralife (NASDAQ:ULBI) stock rose 17.27% to $10.24. The company's market cap stands at $168.4 million. The company's, Q1 earnings came out today. P.A.M. Transportation (NASDAQ:PTSI) stock increased by 12.17% to $16.31. The company's market cap stands at $359.3 million. TransUnion (NYSE:TRU) stock moved upwards by 12.11% to $77.0. The company's market cap stands at $14.9 billion. As per the news, the Q1 earnings report came out today. Nauticus Robotics (NASDAQ:KITT) stock rose 8.21% to $0.21. The company's market cap